C
Christopher Cioffi
Researcher at UCB
Publications - 17
Citations - 722
Christopher Cioffi is an academic researcher from UCB. The author has contributed to research in topics: Psoriasis Area and Severity Index & Psoriasis. The author has an hindex of 8, co-authored 15 publications receiving 340 citations.
Papers
More filters
Journal ArticleDOI
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
Kim A. Papp,Joseph F. Merola,Alice B. Gottlieb,Christopher E.M. Griffiths,Nancy Cross,Luke Peterson,Christopher Cioffi,Andrew Blauvelt +7 more
TL;DR: Dual neutralization of IL‐ 17A and IL‐17F with bimekizumab provided rapid and substantial clinical improvements in patients with psoriasis, with no unexpected or dose‐related safety findings.
Journal ArticleDOI
Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study
Josef S Smolen,Gerd-Rüdiger Burmester,Bernard Combe,Jeffrey R. Curtis,Stephen Hall,Boulos Haraoui,Ronald F van Vollenhoven,Christopher Cioffi,C. Ecoffet,L. Gervitz,Lucian Ionescu,Luke Peterson,Roy Fleischmann +12 more
TL;DR: These results show that certolizumab pegol plus methotrexate is superior to adalimumab plus adal balances plus clinical benefit and clinical benefit show the efficacy and safety of switching to the other TNF inhibitor without a washout period after insufficient primary response to the first TNF inhibitors at week 12.
Journal ArticleDOI
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Kristian Reich,Kim A. Papp,Andrew Blauvelt,Richard G. Langley,April W. Armstrong,Richard B. Warren,Kenneth B. Gordon,Joseph F. Merola,Yukari Okubo,Cynthia Madden,Maggie Wang,Christopher Cioffi,Veerle Vanvoorden,Mark Lebwohl +13 more
TL;DR: Bimekizumab was more efficacious than ustekinumab and placebo in the treatment of moderate to severe plaque psoriasis and the bimekzumab safety profile was consistent with that observed in previous studies.
Journal ArticleDOI
Bimekizumab versus Secukinumab in Plaque Psoriasis.
Kristian Reich,Richard B. Warren,Mark Lebwohl,Melinda Gooderham,Bruce Strober,Richard G. Langley,Carle Paul,Dirk De Cuyper,Veerle Vanvoorden,Cynthia Madden,Christopher Cioffi,Luke Peterson,Andrew Blauvelt +12 more
TL;DR: Bimekizumab as discussed by the authors is a monoclonal IgG1 antibody that selectively inhibits both interleukin-17A and interleuxin 17F.
Journal ArticleDOI
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
Kenneth B. Gordon,Peter Foley,James G. Krueger,Andreas Pinter,Kristian Reich,Ronald Vender,Veerle Vanvoorden,Cynthia Madden,Katy White,Christopher Cioffi,Andrew Blauvelt +10 more
TL;DR: The BE READY trial as discussed by the authors investigated the efficacy and safety of bimekizumab in patients with moderate to severe plaque psoriasis, the effects of treatment withdrawal, and two maintenance dosing schedules over 56 weeks.